RE:RE:RE:RE:RE:STATINS INCREASE RISK T2D BY UP 46%Sir Holler,
SUSTAIN and ASSURE included patients taking 5, 10 or 20 mg/day of rosuvastatin. I think in some earlier versions of the post-hoc analyses split up the results based on statin dose. I don't have access to these slides, but I recall RVX-208 + rosuvastatin at all doses resulted in significant IVUS plaque volume reduction compared to a similar dose rosuvastatin alone (palcebo group). However, if my memory serves me correctly the greatest plaque volume reduction occured with the higher doses of rosuvastatin.
Keep in mind the SUSTAIN and ASSURE were never designed to test the minimum dose of RVX-208 that is required to achieve the beneficial synergistic effects of rosuvastatin + RVX-208. The patients were on a particular statin standard of care therapy already going into the SUSTAIN and ASSURE trials and whatever dose they were on prior to the trial was likely determined by prior cardiac events or degree of desired LDL lowering , and these same statin doses were continued during RVX-208 treatment.
Bear